艾灸治疗小儿反复呼吸道感染非急性感染期临床疗效

目的 评价艾灸治疗小儿反复呼吸道感染（recurrent respiratory tract infections，RRTI）非急性感染期的临床疗效。方法 将62例RRTI非急性感染期患儿随机分为治疗组30例和对照组32例，治疗组基于辨体质取穴，选取清艾条，采用温和灸法，对照组口服脾氨肽冻干粉，疗程均为4周，随访6个月，比较两组发病次数、证候积分、临床疗效及不良反应。结果 治疗后，两组平均每月发病次数均明显减少，差异有统计学意义（P<0.05）；治疗后两组反复外感积分、面色积分、形体积分、汗出积分、乏力积分及次症积分均较治疗前显著减少（P<0.05），其中治疗组在改善汗出、乏力、次症方面优于对照组（P<0.05）；两组临床疗效比较，治疗组优于对照组（P<0.05）；两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论 艾灸能够有效改善RRTI非急性感染期患儿的临床症状，减少其呼吸道感染复发次数，且不良反应发生率低。

Clinical Effect of Moxibustion in Treatment of Children in Non-acute Stage of Recurrent Respiratory Tract Infection

Objective To investigate the clinical effect of moxibustion in treatment of children in the non-acute stage of recurrent respiratory tract infection (RRTI). Methods A total of 62 children in the non-acute stage of RRTI were randomly divided into treatment group with 30 children and control group with 32 children. The children in the treatment group were given mild-warm moxibustion with moxa stick at the acupoints selected based on body constitution, and those in the control group were given Spleen Aminopeptide Oral Lyophilized Powder. The course of treatment was four weeks for both groups, and the children were followed up for 6 months. The two groups were compared in terms of number of attacks, change in syndrome score, clinical outcome, and adverse events. Results Both groups had a significant reduction in the number of attacks after treatment (P<0.05). Both groups also had significant reductions in the scores of recurrent exogenous disease, complexion, body shape, sweating, weakness, and minor symptoms after treatment (P<0.05), and the treatment group had significantly greater improvements in sweating, weakness, and minor symptoms than the control group (P<0.05). The treatment group had significantly better clinical outcomes than the control group (P<0.05), and there was no significant difference in the incidence rate of adverse events between the two groups (P>0.05). Conclusion Moxibustion can significantly improve the clinical symptoms of children in the non-acute stage of RRTI and reduce the recurrence of respiratory infection, with a low incidence rate of adverse events.